Clinical Trials Browser

Phase 2 × Thyrotropin Alfa × 90 days × Clear all

NCT03841617 2026-02-17

The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer

Phase 2 Recruiting

Neoplasm Metastasis, Thyroid Neoplasms

NCT06440850 2026-02-02

Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation

Phase 2 Recruiting

EndocrineHead & Neck

Thyroid Cancer, Papillary, Adenocarcinoma, Follicular